DiaMedica Therapeutics Inc. — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
DiaMedica is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant human tissue kallikrein-1 protein, for acute ischemic stroke (AIS) and cardio-renal disease (CRD). The company has no approved products and generates no product revenue. The report covers the three months ended March 31, 2024, and was filed May 8, 2024.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $3.676 million | $3.618 million | +1.6% |
| General and administrative expense | $2.065 million | $1.903 million | +8.5% |
| Total operating expenses and operating loss | $5.741 million | $5.521 million | +4.0% expense |
| Other income, net | $597 thousand | $256 thousand | +133.2% |
| Net loss | $5.151 million | $5.272 million | 2.3% lower loss |
| Net loss per share | $0.14 | $0.20 | Improved |
| Cash used in operating activities | $6.653 million | $5.089 million | +$1.564 million |
Because the company has no revenue, operating and net profit margins are not meaningful. Accumulated deficit was $120.709 million at March 31, 2024. Share-based compensation was $488 thousand, compared with $422 thousand in the prior-year quarter.
Cash, cash equivalents and marketable securities totaled $46.516 million at March 31, 2024, down from $52.895 million at December 31, 2023. Cash and cash equivalents were $2.097 million, with $44.419 million in short-term marketable securities. Working capital was $44.867 million, compared with $50.889 million at year-end 2023.
Investing activities provided $4.208 million, primarily reflecting marketable-securities maturities exceeding purchases. Financing activities used approximately $1 thousand. The company has no existing credit facilities and reported only limited finance and operating lease obligations; total liabilities were $2.911 million.
Material Changes Versus the Prior Comparable Period
- Operating expenses increased 4.0%, driven by higher R&D and G&A spending.
- R&D expense increased modestly as ReMEDy2 activities continued, partly offset by completion of certain prior-year clinical and in-use study work.
- G&A expense increased primarily because of higher personnel costs, partly offset by lower directors’ and officers’ insurance premiums.
- Interest-related other income increased to $597 thousand because of higher marketable-securities balances during the quarter.
- Operating cash burn increased by $1.564 million, primarily because the company advanced $1.308 million in deposits to clinical-trial vendors.
- Weighted-average shares increased to 37.958 million from 26.449 million, reflecting prior equity financing activity; 5,916 shares were issued upon restricted stock unit vesting during Q1 2024.
Guidance, Outlook, Risks and Unusual Items
DiaMedica is conducting the Phase 2/3 adaptive-design ReMEDy2 trial of DM199 in AIS. The trial is intended to enroll approximately 350 participants at up to 100 global sites, with physical recovery measured by the modified Rankin Scale at day 90 as the primary endpoint. The company is expanding the trial internationally and is preparing regulatory submissions and engaging sites in Canada, Australia, the United Kingdom and Europe.
Management expects R&D expenses and monthly negative cash flow to increase relative to recent periods as the trial expands and enrollment progresses. G&A expenses are expected to remain generally steady. The company expects to disclose plans for its cardio-renal program in the second half of 2024.
Management believes current cash, cash equivalents and marketable securities are sufficient to fund planned operations and the ReMEDy2 trial for at least the next 12 months from the issuance of the financial statements. However, the company expects to require substantial additional capital to advance clinical development and regulatory activities. Additional financing may be needed earlier than anticipated and could dilute shareholders or require unfavorable strategic arrangements.
Key clinical risks include slower-than-expected site activation and enrollment, hospital staffing shortages, competition for trial sites and participants, protocol-compliance challenges, prior clinically significant hypotension events and the former clinical hold, which was lifted in June 2023. Delays or unfavorable clinical results could materially affect financing needs and the development program.
In litigation with ICON/PRA Netherlands, a Dutch court previously affirmed DiaMedica’s ownership of relevant clinical-study data but rejected its damages claim for lack of sufficient causal connection. DiaMedica notified the court and ICON/PRA of its intent to appeal. An appeal hearing regarding the document-related decision is scheduled for September 23, 2024. The filing does not provide a clear estimate of any potential financial recovery or loss.
Important Facts for Investors to Verify
- ReMEDy2 enrollment, site activation, global expansion progress and timing of interim analysis or other trial milestones.
- Whether the company’s projected cash runway remains at least 12 months as clinical spending increases.
- Potential timing, size, terms and dilution effects of future equity, debt or strategic financing.
- Clinical safety data, particularly any recurrence of hypotension events or other issues affecting the prior clinical hold.
- Regulatory submissions and development plans for the CRD program expected in the second half of 2024.
- Outcome and financial implications of the ICON/PRA Netherlands appeals and related litigation.
- Future R&D costs, enrollment-related deposits and the company’s ability to maintain trial funding without product or licensing revenue.